formulations of fenoldopam are disclosed for repeated administration or continued slow release administration , over prolonged periods of time or targeted slow and regulated delivery . the formulations include those formulations that increase the bioavailability of fenoldopam after oral intake , particularly lipid based nano dispersions and pronanodispersions and surfactant rich formulations . this may be accomplished by entrapment in nanoparticles or liposomal formulations or conjugation to a polymer or small molecule via a soft bond .